IFNA1 and melanoma: In addition, patients with IFN algorithm low who remain low on treatment do not respond even in nivolumab/ipilimumab combination (87).Together, these findings indicate the existence of a molecular context linking melanoma dedifferentiation and IFN-γ-signaling and the perturbation of this balance by the IFN-regulated messages may lead to immune evasion and may adjust ICI responsiveness, independent of tumor mutational burden (88).